质量驱动价值升级，博雅干细胞以全链高标准把握时代机遇

Core Insights - The report from Toubao Research Institute highlights the accelerating industrialization of China's stem cell industry, with a shift in focus from scale expansion to the construction and optimization of a comprehensive quality system [1][2] Industry Overview - The global landscape of stem cell research is becoming clearer, with the United States leading in clinical research projects, totaling 2,901, which accounts for 53% of the global market. China follows with 586 projects, ranking second [1] - The establishment of a quality management system compliant with GMP standards is becoming a survival threshold and core competitiveness for stem cell companies [2] Company Positioning - Boya Stem Cells, as a leading enterprise in the industry, emphasizes high standards across the entire chain, leveraging quality control and technological innovation to seize high-quality development opportunities [1][3] - The company has developed a standardized system covering the entire lifecycle of stem cell management, from sample collection to storage, supported by proprietary technologies such as the BACCS® temperature monitoring system and AXP® automated separation equipment [2] Clinical Applications and Innovations - China's clinical research projects are primarily focused on high-incidence areas such as respiratory and neurological diseases, with clinical translation entering an accelerated realization phase [3] - Boya Stem Cells is actively exploring the application value of stem cell technology in fields like osteoarthritis and neurodegenerative diseases, while also expanding into emerging areas such as exosomes [3] Future Outlook - The transition towards high-quality development in the industry is crucial for empowering industrial upgrades and benefiting public health. Boya Stem Cells aims to continue leading the industry with high standards, focusing on technological innovation and clinical translation [3]